Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Tyra Bioscience and keeping the price target at $30.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mitchell Kapoor has given his Buy rating due to a combination of factors surrounding Tyra Bioscience’s promising developments in treating non-muscle invasive bladder cancer (NMIBC) and achondroplasia (ACH). The company’s lead candidate, dabogratinib, is poised to become the first oral FGFR3 therapy for NMIBC, with a significant advantage in convenience over current treatments. The anticipated Phase 2 data in the first half of 2026 is expected to show a complete response rate of around 70% at three months, which could lead to a paradigm shift in treatment approaches.
Furthermore, Tyra Bioscience’s selective FGFR3 inhibition strategy aims to achieve significant growth rates and reduce skeletal complications in achondroplasia patients. The initial pediatric data expected in the second half of 2026 will be crucial, with the company targeting an annual height velocity exceeding 8-9 cm/year. This approach, coupled with a cleaner safety profile and the potential for strong market uptake, underpins Kapoor’s confidence in the stock’s future performance, leading to the reiterated Buy rating and a 12-month price target of $30 per share.
According to TipRanks, Kapoor is an analyst with an average return of -11.3% and a 40.32% success rate. Kapoor covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Ionis Pharmaceuticals, and Summit Therapeutics.
In another report released yesterday, Piper Sandler also maintained a Buy rating on the stock with a $33.00 price target.